Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-286-2 | CAS number: 137-26-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 Nov - 10 Dec 1988
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
- Principles of method if other than guideline:
- No guideline followed. Range-finding study with mice as test organism, used for a 78 week carcinogenicity study
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Thiram
- EC Number:
- 205-286-2
- EC Name:
- Thiram
- Cas Number:
- 137-26-8
- Molecular formula:
- C6H12N2S4
- IUPAC Name:
- thiram
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- CD-1
- Remarks:
- Crl:CD-1(ICR)BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc, Portage, Michigan, USA
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 5 - 6 weeks
- Weight at study initiation: group mean was 24.3 - 24.8 g for males and 19.0 - 19.3 g for females
- Fasting period before study: not applicable
- Housing: individually in stainless steel, screen-bottomed cages
- Diet: Certified rodent chow #5002 (Purina Mills, Inc), ad libitum
- Water: tap water, ad libitum
- Acclimation period: 10 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.6 - 23.9
- Humidity (%): 30 - 70
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 10 Nov 1988 To: 10 Dec 1988
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet: weekly
- Mixing appropriate amounts with: the appropriate amount of Certified Rodent Chow #5002 was weighed in to a Hobart mixing bowl. 250 g of food was taken from this bowl and added with the appropriate amount of the test material to a Waring blender. This premix was mixed thoroughly and then trasnferred to the Hobart mixing bowl. Then 100 g of additional food was blended to remove residual test material from the blender.
- Storage temperature of food: frozen until in use - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Data for stability and homogeneity of similar diets were available from a previous toxicity study.
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- continuously via the diet
Doses / concentrationsopen allclose all
- Dose / conc.:
- 300 ppm
- Remarks:
- corresponding to approx. 51 – 58 mg/kg bw/day for males and 59 – 66 mg/kg bw/day for females
- Dose / conc.:
- 600 ppm
- Remarks:
- corresponding to approx. 101 – 115 mg/kg bw/day for males and 111 – 127 mg/kg bw/day for females
- Dose / conc.:
- 1 200 ppm
- Remarks:
- corresponding to approx. 177 – 226 mg/kg bw/day for males and 221 – 281 mg/kg bw/day for females
- No. of animals per sex per dose:
- 10
- Control animals:
- yes
- Details on study design:
- - Fasting period before blood sampling for clinical biochemistry: yes (overnight)
- Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily for moribundity and mortality and once daily for signs of toxicity
BODY WEIGHT: Yes
- Time schedule for examinations: immediately before start of treatment, on Day 0, weekly thereafter and at termination.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: after 4 weeks of treatment
- Anaesthetic used for blood collection: Yes (ketamine)
- Animals fasted: Yes (overnight)
- How many animals: all animals of all groups (treatment and control)
- Parameters checked: red blood cell (RBC) count, haemoglobin (Hb), haematocrit (Hc), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), platelet count (PLT), white blood cell count (WBC), differential leucocyte count, including nucleated red blood cell count (NRBC), corrected white blood cell count (COR WBC), segmented neutrophil count (N-SEG), band neutrophil count (N-BAND), lymphocyte count (LYMPH), monocyte count (MONO), eosinophil count (EOSIN), basophil count (BASO), morphology.
CLINICAL CHEMISTRY: Yes
- Anaesthetic used for blood collection: Yes (ketamine)
- Animals fasted: Yes (overnight)
- How many animals: all animals of all groups (treatment and control)
- Parameters checked: Glucose (GLU), urea nitrogen (UN), total protein (T PRO), albumin (ALB), globulin (GLOB), alanine aminotransferase (ALT)
PLASMA/SERUM HORMONES/LIPIDS: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Animals were anesthetized with methoxyflurane, weighed, exsanguinated and necropsied.
Organs weighed: Brain, kidneys, liver with gallbladder, ovaries, testes
HISTOPATHOLOGY: Yes
- Tissues sampled in 10% buffered formalin: Adrenals, aorta, bone, bone marrow, brain, caecum, cervix, colon, duodenum, epididymides, eyes, femur, oesophagus, gallbladder, gross lesions, heart, ileum, jejunum, kidneys, liver, lungs, lymph nodes, mammary gland, muscle, ovaries, pancreas, parathyroid, prostate, sciatic nerve, pituitary, rectum, salivary glands, seminal vesicles, skin, spinal cord, spleen, sternum, stomach, testes, thymus, thyroid gland, trachea, urinary bladder, uterus, vagina.
- embedding media: Paraffin
- Staining: haematoxylin and eosin
- Examined for: all animals of the control and high-dose group. Macroscopic lesions, lungs, liver with gallbladder and kidneys were also examined microscopically from all animals of the low and mid dose group. - Statistics:
- Levene's test was applied to test for heterogeneity of variance between treatments. Where significant heterogeneity was found, a logarithmic, square, square root, reciprocal, angular or rank transformation was tried to see if a more stable variance structure could be obtained.
If no significant heterogeneity was detected (or if a satisfactory transformation was found), a one-way analysis of variance (ANOVA) was carried out. If significance was found, a Dunnett's t-test was used for pairwise comparison.
If significant heterogeneity of variance was present, and could not be removed by a transformation, the Kruskal-Wallis H-test ANOVA was used. If this was significant, the Nemenyi-Kruskal-Wallis test for multiple comparisons or the Wilcoxon-Mann-Whitney two-sample rank test was used.
Statistical significance was defined at the 5% two tailed probability level.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- - Control: alopecia (1/10 males)
- 300 ppm: hunched posture (1/10 males), animal was thin (1/10 males), alopecia (1/10 males), squinting of both eyes (1/10 males), bloody crust on the tail (1/10 females), red tail (1/10 females), necrotic tail (1/10 females).
- 600 ppm: animal was thin (1/10 females), alopecia (1/10 females), opaque red eye (1/females)
- 1200 ppm: hunched posture (1/10 males, 2/10 females), animal was thin (1/10 males, 2/10 females), alopecia (1/10 females), lacrimation in the left eye (1/10 males)
The hunched posture and the occurrence of thin animals was considered treatment related. All other signs were considered incidental. - Mortality:
- no mortality observed
- Description (incidence):
- No mortality was observed during the study.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- - 300 ppm: body weight and body weight gain were statistically significantly lower in males compared to the control group in Week 3 and 4.
- 600 ppm: body weight and body weight gain were statistically significantly lower in males compared to the control group in Week 4.
- 1200 ppm: body weight was statistically significantly lower in males compared to the control group in Week 3 and 4. Body weight gain was statistically significantly lower compared to the control in Weeks 2 - 4 for males and for Weeks 3 and 4 for females.
Summarized results can be found in Attachment 1 in the attached background material. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- - 300 ppm: food consumption was statistically significantly decreased during the complete treatment period.
- 600 ppm: food consumption was statistically significantly decreased during the complete treatment period.
- 1200 ppm: food consumption was statistically significantly decreased during the complete treatment period.
Summarized results can be found in Attachment 1 in the attached background material. - Food efficiency:
- not examined
- Description (incidence and severity):
- not applicable
- Water consumption and compound intake (if drinking water study):
- not examined
- Description (incidence and severity):
- not applicable
- Ophthalmological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- - 300 ppm: decreased RBC (males -6.5%), slightly decreased Hb (males -6.2%), slightly decreased Hct (males -5.1%), all changes were statistically significantly different from the control group.
- 600 ppm: decreased RBC (males -7%, females -6.2%), slightly decreased Hb (males -5%), slightly decreased Hct (males -5.1%), increased platelet count (females +18.8%), all changes were statistically significantly different from the control group.
- 1200 ppm: decreased RBC (males -7.3%), slightly decreased Hb (males -8.6%), slightly decreased Hct (males -7.7%), increased platelet count (females +27.6%), all changes were statistically significantly different from the control group.
Although these changes were statistically significant and most were treatment-related, they were relatively small and not considered indicative of severe primary pathologic effects.
Summarized results can be found in Attachment 1 in the attached background material. - Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- The only statistically significant difference was decreased glucose in females of the 1200 ppm group. This was not considered treatment-related but incidental. Apart from that, no difference was observed in clinical chemistry between the treatment and control groups.
Summarized results can be found in Attachment 1 in the attached background material. - Endocrine findings:
- not specified
- Description (incidence and severity):
- The following ED-related parameters were investigated in the study: histopathology of cervix, epididymis, mammary gland, ovary, prostate, seminal vesicles, testis, thyroid, uterus, vagina and adrenals, organ weights were recorded for epididymis, liver, prostate, testis and brain. For details, please refer to the respective result fields and the endpoint summary.
- Urinalysis findings:
- not examined
- Description (incidence and severity):
- not applicable
- Behaviour (functional findings):
- not examined
- Description (incidence and severity):
- not applicable
- Immunological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- - 300 ppm: the relative brain weight was statistically significantly higher in males compared to the control group.
- 600 ppm: increased relative liver weight (males +12.7%), and kidney weight (males +15.1%), decreased absolute brain weight was observed in males (-6.2%), all differences were statistically significant compared to the control group.
- 1200 ppm: increased relative liver weight (females +11%, males +13.8%), all differences were statistically significant compared to the control group.
These changes are considered secondary to decreased terminal body weight.
Summarized results can be found in Attachment 1 in the attached background material. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No treatment related difference was observed between control and treatment groups up to and including the highest dose level.
Summarized results can be found in Attachment 1 in the attached background material. - Neuropathological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No treatment related difference was observed between control and treatment groups up to and including the highest dose level.
Summarized results can be found in Attachment 1 in the attached background material. - Histopathological findings: neoplastic:
- not examined
- Description (incidence and severity):
- not applicable
Effect levels
open allclose all
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 300 ppm
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- haematology
- organ weights and organ / body weight ratios
- Remarks on result:
- other: corresponding to 51 mg/kg bw/day.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 300 ppm
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: No adverse effects were observed at this dose level.
- Remarks on result:
- other: corresponding to 59 mg/kg bw/day.
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 600 ppm
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- haematology
- organ weights and organ / body weight ratios
- Remarks on result:
- other: corresponding to 127 mg/kg bw/day.
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- The present study was conducted to assess the sub-acute toxicity of test substance on mice when given for a time frame of 4 weeks. The study was not conducted according to any guideline as it served as a dose-range finder. It was performed under GLP conditions. The test substance was administered via dietary exposure to groups of 10 male and female mice at dose levels of 300, 600 and 1200 ppm corresponding to approximately 51-58, 101-115 and 177-226 mg/kg bw/day for males and 59-66, 111-127 and 221-281 mg/kg bw/day for females.
There were no mortalities during the study. Body weights were significantly lower for males in the 300 and 1200 ppm groups during Week 3 and 4 and for males in the 600 ppm group for Week 4. Females showed no differences. Food consumptions were significantly lower for all treated animals throughout the study period. RBC count, Hb and Hc were slightly lower in all treated males. In females RBC count was decreased in the 600 ppm group while platelet count was increased at 600 and 1200 ppm. The only statistically significant alteration in clinical chemistry was the decreased glucose value in females dosed at 1200 ppm. Absolute organ weights alterations were not dose-response-related and regarded as a result of the lower terminal body weight. There were no treatment-related macroscopic or microscopic observations noted.
Based on reduced food consumption and enhanced platelet count, the no-observable-adverse-effect level (NOAEL) for the test substance when fed to female mice for 4 weeks was 300 ppm (corresponding to 59-66 mg/kg bw for females). Due to the effects observed in the low dosed male group, a NOAEL for males could not be determined.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.